A Phase 3 interventional study of VK2735 and Placebo comparator in Weight Loss, sponsored by Viking Therapeutics, Inc.. Recruiting at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Viking Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 998 studies in Weight Loss with a site in United States — 117 open to participants now, 172 under way, 8 of them phase 3. Weight Loss · United States.
Among the 998 studies in Weight Loss with a site in United States, this one is the 50th largest by planned enrollment of the 915 interventional ones that give a count, is one of 48 that started in 2026, is one of 32 in phase 3, reaches primary completion later than 132 of the 171 other live ones, and was the 993rd registered.
1,818 studies on the registry are indexed under Weight Loss; 296 are open to participants now.
Browse Weight Loss studies →117 of the 998 studies in Weight Loss with a site in United States are open now. Recruiting first, the newest first:
Viking Therapeutics, Inc. · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 6+
Morehouse School of Medicine · Sites in United States
Ages 12+ · Healthy volunteers
Duke University · Sites in United States
Ages 21–90 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 199 Weight Loss studies recruiting now, 73 (37%) set no upper age limit and 109 (55%) stop at 75 or younger; 21 take children under 18; 57 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
998 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 106 · Phase 3 40 · Phase 4 33
First in 1996; this study’s year is marked. 48 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 560 is above the median of 80 across 1,564 interventional studies indexed under Weight Loss.
Median enrollment 72 across the 915 interventional studies, 99 across the 76 observational. Of the 769 that completed or were terminated, 231 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 998 have an industry lead sponsor. The 10 most frequent:
Viking Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Viking Therapeutics, Inc. has 9 studies filed under Weight Loss — fewer than ten, so there is no comparison to draw.
58 of the studies in Weight Loss with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07298915Phase 3University of VirginiaThe Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | 2026-12 |
| NCT07223242Phase 3University of Texas Southwestern Medical CenterTailored Exercise Training Study Among Adults With HFpEF | 2026-12-30 |
| NCT07104383Phase 3Viking Therapeutics, Inc.VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | 2027-07-01 |
| NCT07104500Phase 3Viking Therapeutics, Inc.VK2735 for Weight Management Phase 3 | 2027-07-01 |
| NCT07560579Million Marker Wellness, Inc.Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity | 2026-11 |
Add all 58 to your calendar (.ics) → With an account.
Among the 998 studies in Weight Loss with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults who are obese or overweight with one or more weight related comorbid conditions without Type 2 Diabetes Mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo comparator orally once daily
Drug: Placebo comparator
VK2735 Dose level 1 orally once daily
Drug: VK2735
VK2735 Dose level 2 orally once daily
Drug: VK2735
VK2735 Dose level 3 orally once daily
Drug: VK2735
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily
Placebo comparator administered orally once daily
Percentage change in body weight for participants receiving VK2735 orally once daily
To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68
Time frame: 68 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jul 2028, 20 months later.
Of 23 phase 3 interventional studies under Weight Loss, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's planned 20 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VK2735